Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

ClinicalTrials.gov ID: NCT00103727

Public ClinicalTrials.gov record NCT00103727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate whether talnetant (200mg, 400mg, 600mg) twice a day is effective compared to placebo and risperidone 1-3mg twice a day in treating the positive and negative symptoms of schizophrenia. Study subjects will be treated with study drug for up to 6 weeks and will then return for a follow-up visit 2 weeks later. About 275 patients with schizophrenia will be enrolled in this study.

Study identification

NCT ID
NCT00103727
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
282 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2004 (Type not available)
Primary completion
Oct 2005 (Actual)
Completion
Oct 2005 (Actual)
Last update posted
Apr 29, 2015

2004 – 2005

United States locations

U.S. sites
22
U.S. states
11
U.S. cities
21
Facility City State ZIP Site status
GSK Investigational Site Little Rock Arkansas 72201 —
GSK Investigational Site Anaheim California 92805 —
GSK Investigational Site Cerritos California 90703 —
GSK Investigational Site Garden Grove California 92845 —
GSK Investigational Site Glendale California 91206 —
GSK Investigational Site National City California 91950 —
GSK Investigational Site Oceanside California 92056 —
GSK Investigational Site Pico Rivera California 90660 —
GSK Investigational Site Rosemead California 91770 —
GSK Investigational Site San Diego California 92123 —
GSK Investigational Site San Diego California 92126 —
GSK Investigational Site Upland California 91786 —
GSK Investigational Site Washington D.C. District of Columbia 20016 —
GSK Investigational Site North Miami Florida 33161 —
GSK Investigational Site Atlanta Georgia 30308 —
GSK Investigational Site Oak Brook Illinois 60523 —
GSK Investigational Site St Louis Missouri 63118 —
GSK Investigational Site Clementon New Jersey 08021 —
GSK Investigational Site Philadelphia Pennsylvania 19131 —
GSK Investigational Site Austin Texas 78756 —
GSK Investigational Site Irving Texas 75062 —
GSK Investigational Site Richmond Virginia 23294 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00103727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 29, 2015 · Synced Oct 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00103727 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →